Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
about
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studiesSingle dose oral lumiracoxib for postoperative painOral non steroid anti-inflammatories for children and adults with bronchiectasisEffects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal functionCardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysisA turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityMolecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxenTapentadol hydrochloride: A novel analgesicNew horizons and perspectives in the treatment of osteoarthritisTaking the stress out of managing goutThe specialist physician's approach to rheumatoid arthritis in South AfricaManaging osteoarthritisNew insights into the use of currently available non-steroidal anti-inflammatory drugsPiroxicam-β-cyclodextrin: a GI safer piroxicamFire-Needle Moxibustion for the Treatment of Knee Osteoarthritis: A Meta-AnalysisNonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational StudiesReduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control studyAn economic model of long-term use of celecoxib in patients with osteoarthritisThe David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environmentDiclofenac prolongs repolarization in ventricular muscle with impaired repolarization reserveComparison of pooled risk estimates for adverse effects from different observational study designs: methodological overviewRisk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias ToolChemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysisNSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studiesAnti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema.Alleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory DrugsClinical Pharmacology and Cardiovascular Safety of NaproxenOptimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis.Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective dataSafe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksHow do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative.The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.Does rectal indomethacin given for prevention of post-ERCP pancreatitis increase bleeding after biliary endoscopic sphincterotomy or cardiovascular mortality?: Post hoc analysis using prospective clinical trial data.Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.ADAPT: the wrong way to stop a clinical trial.EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.Non-steroidal anti-inflammatory drugs in the treatment of genitourinary malignancies: focus on clinical data.Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
P2860
Q21144617-9F315E25-5736-4251-8709-C2F3F00A1E15Q24242935-B615EB96-5839-4FB6-84F6-416C7DF4AE5CQ24242964-0BF654ED-C680-4380-BFE2-CB1F741E2DAAQ24245290-DBC5CE9F-0A78-4D8F-9C07-FABAF479A1B7Q24601392-83217D8E-1B8F-436E-8142-46CA298C8A2BQ24615651-1EC89036-6485-4C90-A3A9-532EF5CBE2C1Q24621123-B1160E29-E2FC-43F5-B397-A96C5298648AQ24629365-2F54C06C-98F0-42AD-8C79-6B5BEC89881FQ24657795-3AAE8E3B-7B83-4052-A3FD-A1079D926379Q24658037-F93BDE65-B767-4F5C-B785-066506C3E311Q26765122-613A0C6D-B48B-4ADD-B98D-EF775E2C1422Q26773279-9F5C0A11-970A-4434-AA88-AEF7470CA2EAQ26852330-C9A8B45F-07C0-4D43-A6C1-D25AADA2856AQ27023475-F8D72EE5-4620-4057-9B58-489FDBD7E42DQ28069657-0892C475-5F0E-43CA-894F-9A0C0F62D99EQ28079436-AAD727D9-1194-4600-83AB-148A91237AF4Q28217572-527E3E74-DED5-4CDE-B231-AFB24A845F9EQ28218005-30E080ED-FF1D-45E3-B0EB-05B4DEF98EE0Q28222253-8D56193A-6C02-4B55-B44E-C74E04A1460CQ28484663-F57BE046-07C2-495C-9C31-849487318FB1Q28535464-64A129F4-F052-44A8-9C62-48D0E8DC56E1Q28551188-9A13ED1E-3B5A-426E-8AC9-B63CA396BAF8Q28589784-28F5F08C-01E0-4502-8916-6A5712839485Q28742977-C634057E-6268-4B47-9B37-434B3FA698CDQ29346992-99B0FD9E-17E7-43C1-8338-2E4BFDDF401BQ30234292-93940CF3-07A5-4E5F-8A79-0C8A0AD81520Q30360728-FB13C50D-E5E1-46A5-BA5E-AC4E71650082Q30537079-9C876F2F-0899-4929-9C70-79DBA452A0E8Q30540294-974027CD-8BF4-4968-A0C7-FD34726E9A2FQ30570853-7589E316-BDF2-4117-BEAD-940C2486F271Q30629677-A61CBCB6-C58A-4692-AFE6-186839591B84Q30665172-F4F512EE-2E7F-4DA9-B5E8-2868DDCA5D90Q30791071-559BB9CF-44DE-4066-9E16-196EFC840819Q30812957-29A2A570-EC88-423D-8C76-2F4137FE58ECQ30874316-B610AC02-6655-418B-8CB2-298D5E360BF6Q30994474-22AE2A8B-3838-4FC8-A3C0-91760BE0F5A1Q33263888-01037315-A605-4545-9D8E-476A1EC6016EQ33292103-AA80C678-0493-41FA-BE78-1C42157F26EEQ33304363-CA4F2F9F-225B-4038-979B-D97410604648Q33323076-2ADB7AE8-E6B6-4ACE-A171-9F5502AD9A56
P2860
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cardiovascular risk and inhibi ...... nhibitors of cyclooxygenase 2.
@ast
Cardiovascular risk and inhibi ...... nhibitors of cyclooxygenase 2.
@en
type
label
Cardiovascular risk and inhibi ...... nhibitors of cyclooxygenase 2.
@ast
Cardiovascular risk and inhibi ...... nhibitors of cyclooxygenase 2.
@en
prefLabel
Cardiovascular risk and inhibi ...... nhibitors of cyclooxygenase 2.
@ast
Cardiovascular risk and inhibi ...... nhibitors of cyclooxygenase 2.
@en
P1476
Cardiovascular risk and inhibi ...... nhibitors of cyclooxygenase 2.
@en
P2093
Patricia McGettigan
P304
P356
10.1001/JAMA.296.13.JRV60011
P407
P50
P577
2006-09-12T00:00:00Z